Is the rate of PML in patients after 2 years (1/100) of Tysabri when it’s administered at the 4 week interval dose or at the extended 6 week dose?
Is the rate of PML in patients after 2 years (1/100) of Tysabri when it’s administered at the 4 week interval dose or at the extended 6 week dose? I found charts of this but wasn’t sure of the interval being accounted for.
Thanks again for your help and time, the content on this site had been very helpful for me and I’m sure others as well.
The risk of PML after 2 years of treatment with Tysabri, when it is administered using the standard dosing regimen (300 mg iv every 4 weeks), is approximately 1 in 100 (1%) for people with a JCV index > 1.5 and no prior history of immunosuppression and approximately 1 in 100 (1%) for people with ANY positive JCV Index and a prior history of immunosuppression.
Revere P (Rip) Kinkel, MD
Professor of Clinical Neurosciences
Director of the Multiple Sclerosis Program
Clinical Neurosciences Director
University of California San Diego
PLEASE NOTE: This information/opinions on this site should be used as an information source only. This information does not create any patient-HCP relationship, and should not be used as a substitute for professional diagnosis and treatment. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition.